MentalHealthDaily

Trends in U.S. Medicaid Antidepressant Prescriptions: Newer Drugs & Higher Costs (2023 Analysis)

by GLOOM

The U.S. Medicaid program’s spending and prescribing patterns for antidepressants between 2017 and 2021 reveal a significant shift toward newer and costlier medications. Highlights: Rising Expenditure: Medicaid’s spending on antidepressants increased from approximately $1 billion in 2017 to $1.12 billion in 2021. Preference Shift: There’s been a significant shift from older antidepressants like TCAs and …

Best Antidepressants for Preventing Depression Relapse & Maintenance Treatment (Study)

by GLOOM

Depression is a complex, often long-term condition requiring careful management. Recent research has shed light on the effectiveness of various antidepressants during the maintenance phase of major depressive disorder (MDD). Highlights: Extensive Study: The meta-analysis included 34 double-blind, placebo-controlled trials with a total of 9,384 participants. Multiple Drugs Analyzed: 20 different antidepressants were compared for …

Exercise to Treat Depression: Aerobic & Resistance Training Effective Antidepressants?

by GLOOM

Exercise has emerged as an effective treatment for depression, rivaling medication and psychotherapy in its ability to reduce symptoms. Both aerobic and resistance training provide mental health benefits, with a combination of the two being optimal. However, exercise is vastly underutilized and more research is needed to uncover the mechanisms behind its antidepressant effects. Highlights: …

Prolonged Antidepressant Effect of Ketamine: NMDA Receptors & Lateral Habenula “Trapping”

by GLOOM

Ketamine causes rapid and sustained antidepressant effects that last longer than its presence in the body. This is due to ketamine getting trapped and accumulating in NMDA receptors, causing prolonged neural inhibition. Manipulating brain activity can shorten or extend ketamine’s effects. Highlights: Ketamine continues blocking NMDA receptors for 24 hours despite rapid elimination from plasma …

NLRP3 Inflammasome & Depression: A Target for Antidepressant Development?

by GLOOM

The NLRP3 inflammasome stands at the crossroads of immune response and mental health, playing a pivotal role in the inflammatory processes implicated in depression. Researchers are exploring the intricate relationship between NLRP3 activation and depressive disorders, highlighting the potential for innovative treatments targeting this complex molecular pathway. Highlights: NLRP3 Inflammasome Activation: NLRP3, a component of …

Mycobacterium vaccae Vaccine: A Novel Soil Bacteria-Based Treatment for Anxiety & Stress Disorders

by GLOOM

Stress can induce anxiety and depression, which appears to be mediated in part by stress-induced neuroinflammatory processes. The immunoregulatory bacterium Mycobacterium vaccae (M. vaccae) has anti-inflammatory and stress-resilient effects, but its impact on the brain is unclear. A study discovered that M. vaccae immunization: induces anti-inflammatory and immunoregulatory processes in the hippocampus, blocks stress-induced neuroinflammation …

Allopregnanolone Agonists for Depression: Brexanolone & Zuranolone in Focus (2023)

by GLOOM

Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …